UroGen Pharma Ltd. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
UroGen Pharma Ltd. (URGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $6.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-10
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $6.93M, a 21.48% increase from fiscal 2023.
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $5.70M, a 442.21% increase from fiscal 2022.
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $1.05M.
- UroGen Pharma Ltd. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $1.44M, a 30.68% decline from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $6.93M 10-K · filed 2025-03-10 |
| 2023-12-31 | $5.70M 10-K · filed 2025-03-10 |
| 2022-12-31 | $1.05M 10-K · filed 2024-03-14 |
| 2020-12-31 | $1.44M 10-K · filed 2021-03-18 |
| 2019-12-31 | $2.08M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |